NASDAQ:AIMT Aimmune Therapeutics Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aimmune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $34.49 0.00 (0.00 %) (As of 10/13/2020) Add Compare Share Today's Range$34.49Now: $34.49▼$34.4950-Day Range$34.30MA: $34.46▼$34.5952-Week Range$10.09Now: $34.49▼$37.00VolumeN/AAverage Volume1.71 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/ABeta1.76 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More MarketRank™Overall MarketRank™1.26 out of 5 starsMedical Sector735th out of 1,922 stocksPharmaceutical Preparations Industry372nd out of 771 stocksAnalyst Opinion: 1.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 1.1 Analyst's Opinion Consensus RatingAimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.28, Aimmune Therapeutics has a forecasted downside of 0.6% from its current price of $34.49.Amount of Analyst CoverageAimmune Therapeutics has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAimmune Therapeutics has received 467 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAimmune Therapeutics has received 326 “underperform” votes. (Add your “underperform” vote.)Community SentimentAimmune Therapeutics has received 58.89% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote “Outperform” if you believe AIMT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAimmune Therapeutics does not currently pay a dividend.Dividend GrowthAimmune Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.75% of the stock of Aimmune Therapeutics is held by insiders.Percentage Held by Institutions74.47% of the stock of Aimmune Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aimmune Therapeutics are expected to grow in the coming year, from ($4.35) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aimmune Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aimmune Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAimmune Therapeutics has a P/B Ratio of 20.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220Employees228Year FoundedN/A Debt Debt-to-Equity Ratio0.73 Current Ratio7.53 Quick Ratio7.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book20.78Profitability EPS (Most Recent Fiscal Year)($3.97) Net Income$-248,500,000.00 Net MarginsN/A Return on Equity-164.99% Return on Assets-89.50%Miscellaneous Outstanding Shares65,450,000Market Cap$2.26 billion Next Earnings DateN/A OptionableOptionable Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions Is Aimmune Therapeutics a buy right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Aimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AIMT, but not buy additional shares or sell existing shares. View analyst ratings for Aimmune Therapeutics or view MarketBeat's top 5 stock picks. What stocks does MarketBeat like better than Aimmune Therapeutics? Wall Street analysts have given Aimmune Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aimmune Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics, Inc. (NASDAQ:AIMT) released its earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.06). View Aimmune Therapeutics' earnings history. What price target have analysts set for AIMT? 9 brokerages have issued 1-year price targets for Aimmune Therapeutics' shares. Their forecasts range from $15.00 to $58.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $34.28 in the next year. This suggests that the stock has a possible downside of 0.6%. View analysts' price targets for Aimmune Therapeutics or view Wall Street analyst' top-rated stocks. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Galapagos (GLPG), Allakos (ALLK), Schrödinger (SDGR), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY) and Perrigo (PRGO). View all of AIMT's competitors. What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the following people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $34.49. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $2.26 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is www.aimmune.com. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] This page was last updated on 1/25/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
